Table 1. FDA-approved and marketed antibody-based cancer therapies.
Currently, cancer patients in the United States have access to 43 different antibody therapeutics, with more than half added in the past five years. The differently colored rows indicate MOAs based on natural or enhanced natural properties of mAbs (green), on engaging cytotoxic T cells (blue), and on delivering cytotoxic payloads (orange).
| Name | Format | Payload | Target | Cancer | Approval |
|---|---|---|---|---|---|
| rituximab (Rituxan®) | chimeric mouse/human IgG1κ | none | CD20 | B-NHL, CLL | 1997 |
| trastuzumab (Herceptin®) | humanized IgG1κ | none | HER2 | breast, stomach | 1998 |
| ibritumomab tiuxetan (Zevalin®) | mouse IgG1κ | 90Y | CD20 | B-NHL | 2002 |
| cetuximab (Erbitux®) | chimeric mouse/human IgG1κ | none | EGFR | colorectal, h & n | 2004 |
| bevacizumab (Avastin®) | humanized IgG1κ | none | VEGF | colorectal, lung, brain, kidney, cervical, ovarian, fallopian, peritoneal, liver | 2004 |
| panitumumab (Vectibix®) | human IgG2κ | none | EGFR | colorectal | 2006 |
| ofatumumab (Arzerra®) | human IgG1κ | none | CD20 | CLL | 2009 |
| ipilimumab (Yervoy®) | human IgG1κ | none | CTLA4 | melanoma, kidney, MSI-H/dMMR colorectal, liver, lung, mesothelioma | 2011 |
| brentuximab vedotin (Adcetris®) | chimeric mouse/human IgG1κ | auristatin | CD30 | HL, T-NHL | 2011 |
| pertuzumab (Perjeta®) | humanized IgG1κ | none | HER2 | breast | 2012 |
| ado-trastuzumab emtansine (Kadcyla®) | humanized IgG1κ | maytansine | HER2 | breast | 2013 |
| obinutuzumab (Gazyva®) | humanized IgG1κ (glycoengineered Fc) | none | CD20 | CLL, B-NHL | 2013 |
| ramucirumab (Cyramza®) | human IgG1κ | none | VEGFR2 | stomach, colorectal, liver, lung | 2014 |
| pembrolizumab (Keytruda®) | humanized IgG4κ | none | PD1 | melanoma, lung, h & n, HL, bladder, MSI-H/dMMR, stomach, cervical, B-NHL, liver, kidney, esophageal, endometrial, TMB-H, skin, breast (TNBC) | 2014 |
| blinatumomab (Blincyto®) | mouse (scFv)2 (BiTE) | none | CD19×CD3 | B-ALL | 2014 |
| nivolumab (Opdivo®) | human IgG4κ | none | PD1 | melanoma, lung, kidney, HL, h & n, bladder, MSI-H/dMMR colorectal, liver, esophageal, mesothelioma | 2014 |
| dinutuximab (Unituxin®) | chimeric mouse/human IgG1κ | none | GD2 | neuroblastoma | 2015 |
| daratumumab (Darzalex®) | human IgG1κ | none | CD38 | multiple myeloma | 2015 |
| necitumumab (Portrazza®) | human IgG1κ | none | EGFR | lung | 2015 |
| elotuzumab (Empliciti®) | humanized IgG1κ | none | SLAMF7 | multiple myeloma | 2015 |
| atezolizumab (Tecentriq®) | humanized IgG1κ (aglycosylated Fc) | none | PDL1 | bladder, lung, breast (TNBC), liver, melanoma | 2016 |
| olaratumab (Lartruvo®) | human IgG1κ | none | PDGFRA | sarcoma | 2016 |
| avelumab (Bavencio®) | human IgG1λ | none | PDL1 | Merkel cell carcinoma, bladder, kidney | 2017 |
| durvalumab (Imfinzi®) | human IgG1κ (engineered Fc) | none | PDL1 | lung | 2017 |
| inotuzumab ozogamicin (Besponsa®) | humanized IgG4κ | calicheamicin | CD22 | B-ALL | 2017 |
| tisagenlecleucel (Kymriah®) | mouse scFv-based CAR-T | T cell | CD19 | B-ALL, B-NHL (DLBCL, FL) | 2017 |
| gemtuzumab ozogamicin (Mylotarg®) | humanized IgG4κ | calicheamicin | CD33 | AML | 2017 |
| axicabtagene ciloleucel (Yescarta®) | mouse scFv-based CAR-T | T cell | CD19 | B-NHL (DLBCL, FL) | 2017 |
| mogamulizumab-kpkc (Poteligeo®) | humanized IgG1κ (afucosylated Fc) | none | CCR4 | T-NHL | 2018 |
| moxetumomab pasudotox-tdfk (Lumoxiti®) | mouse dsFv | bacterial toxin | CD22 | B-NHL (hairy cell leukemia) | 2018 |
| cemiplimab-rwlc (Libtayo®) | human IgG4κ (S228P hinge) | none | PD1 | cutaneous squamous cell carcinoma, basal cell carcinoma, lung | 2018 |
| polatuzumab vedotin-piiq (Polivy®) | humanized IgG1κ | auristatin | CD79B | B-NHL (DLBCL) | 2019 |
| enfortumab vedotin-ejfv (Padcev®) | human IgG1κ | auristatin | NECTIN4 | bladder | 2019 |
| fam-trastuzumab deruxtecan-nxki (Enhertu®) | humanized IgG1κ | camptothecin | HER2 | breast, stomach | 2019 |
| isatuximab-irfc (Sarclisa®) | chimeric IgG1κ | none | CD38 | multiple myeloma | 2020 |
| sacituzumab govitecan-hziy (Trodelvy®) | humanized IgG1κ | camptothecin | TROP2 | breast (TNBC), bladder | 2020 |
| brexucabtagene autoleucel (Tecartus®) | mouse scFv-based CAR-T | T cell | CD19 | B-NHL (mantle cell lymphoma) | 2020 |
| tafasitamab-cxix (Monjuvi®) | humanized IgG1κ (engineered Fc) | none | CD19 | B-NHL (DLBCL) | 2020 |
| belantamab mafodotin-blmf (Blenrep®) | humanized IgG1κ (afucosylated Fc) | auristatin | BCMA | multiple myeloma | 2020 |
| naxitamab-gqgk (Danyelza®) | humanized IgG1κ | none | GD2 | neuroblastoma | 2020 |
| margetuximab-cmkb (Margenza®) | chimeric IgG1κ (engineered Fc) | none | HER2 | breast | 2020 |
| lisocabtagene maraleucel (Breyanzi®) | mouse scFv-based CAR-T | T cell | CD19 | B-NHL (DLBCL, FL) | 2021 |
| idecabtagene vicleucel (Abecma®) | mouse scFv-based CAR-T | T cell | BCMA | multiple myeloma | 2021 |